Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

»ïÀÎ»ê ¾Æµ¥³ë½Å ¹æ±¤ ³» ÁÖÀÔÀ¸·Î À¯µµµÈ °ú¹Î¼º¹æ±¤ µ¿¹°¸ðµ¨¿¡¼­ ¹æ±¤ ³» Ç×¹«½ºÄ«¸°Á¦ ÁÖÀÔÀÇ È¿°ú Effects of Intravesical Instillation of Antimuscarinics on Bladder Overactivity Induced by Intravesical Instillation of Adenosine Triphosphate in Rats

´ëÇѺñ´¢±â°úÇÐȸÁö 2009³â 50±Ç 4È£ p.396 ~ 400
ÀÌ»óºÀ, ÀÌÀç¿ø, ±è¿ëÅÂ,
¼Ò¼Ó »ó¼¼Á¤º¸
ÀÌ»óºÀ ( Lee Sang-Bong ) 
ÇѾç´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç

ÀÌÀç¿ø ( Lee Je-Won ) 
ÇѾç´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç
±è¿ëÅ ( Kim Yong-Tae ) 
ÇѾç´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç

Abstract


Purpose: Adenosine triphosphate (ATP) from the urothelium acts as a sensory neurotransmitter and is augmented in many diseases, such as overactive bladder. We investigated the effects of intravesical instillation of oxybutynin on ATP-induced bladder overactivity to determine whether this effect is mediated by effects on urothelial muscarinic receptors.

Materials and Methods: Cystometry (at rate of 0.04 ml/min) was performed in female Sprague-Dawley rats (body weight 250 g) under urethane anesthesia (1.2 g/kg). After a 2-hour baseline period, protamine sulfate (10 mg/ml) was instilled for 1 hour, and then ATP (60 mM, pH 6.0) or a mixture of oxybutynin (10?6 M) and ATP (60 mM, pH 6.0) was instilled intravesically. We performed experiments with 4-diphenylacetoxy-N-methylpiperidine methobromide (4-DAMP) and methoctramine by the same methods. Cystometric parameters, such as the intercontraction interval (ICI), pressure threshold (PT), and maximal voiding pressure (MVP), were compared.

Results: With intravesical instillation of ATP after protamine sulfate treatment, the ICI was decreased compared with baseline (ICI: baseline, 487.1¡¾64.8 s; protamine, 450.6¡¾56.1 s; ATP, 229.7¡¾35.3 s; p£¼0.05). Addition of oxybutynin, 4-DAMP, or methoctramine in the ATP solution did not significantly change the ICI compared with ATP solution alone (ICI: oxybutynin, 189.1¡¾32.3 s; 4-DAMP, 161.1¡¾22.8 s; methoctramine, 341.0¡¾ 113.3 s; p£¾0.05). Intravesical instillation of ATP decreased MVP and PT significantly compared with baseline, but MVP and PT were not changed significantly with oxybutynin, 4-DAMP, or methoctramine compared with ATP.

Conslusions: Bladder overactivity induced by intravesical instillation of ATP was not suppressed by intravesical instillation of antimuscarinics. Suppression of ATP-induced bladder overactivity by intravenous oxybutynin is not mediated by urothelial muscarinic receptors

Å°¿öµå

Adenosine triphosphate;Muscarinic antagonists;Rats

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS